Dacomitinib improves chemosensitivity of cisplatin‑resistant human ovarian cancer cells

Xu,Lei; Xu,Ying; Zheng,Jianbing; Zhao,Yun; Wang,Hongcai; Qi,Yushu

doi:10.3892/ol.2021.12830

Dacomitinib improves chemosensitivity of cisplatin‑resistant human ovarian cancer cells

Authors:
- Lei Xu
- Ying Xu
- Jianbing Zheng
- Yun Zhao
- Hongcai Wang
- Yushu Qi
View Affiliations

Affiliations: Obstetrics and Gynecology Department, Maternal and Child Health Hospital of Zibo City, Zibo, Shandong 255022, P.R. China
Published online on: May 29, 2021 https://doi.org/10.3892/ol.2021.12830
Article Number: 569
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non‑small cell lung cancer, head and neck cancer, few studies report its effectiveness in drug‑resistant human OC cells. In the present study, would healing, microplate spectrophotometer analysis, flow cytometry analysis, western blotting and Gene Expression Omnibus (GEO) analysis were used to detect the synergistic effect of dacomitinib and cisplatin in human OC SKOV‑3 or OV‑4 cells. Co‑administration of dacomitinib and cisplatin significantly reduced viability and promoted cell apoptosis of drug resistant OC cells. In addition, dacomitinib increased Cadherin 1 (CDH1) levels and decreased P‑glycoprotein (P‑GP) levels in cisplatin‑resistant OC cells. In addition, GEO analysis demonstrated that dacomitinib inhibited the epidermal growth factor receptor (EGFR) signaling pathway. In summary, dacomitinib improves chemosensitivity of cisplatin in human OC by regulating CDH1 and P‑GP protein levels and inhibiting the EGFR signaling pathway.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Reid BM, Permuth JB and Sellers TA: Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32. 2017. View Article : Google Scholar : PubMed/NCBI
3	Kossaï M, Leary A, Scoazec JY and Genestie C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49. 2018. View Article : Google Scholar
4	Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M and Panici PB: Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 100:455–461. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ray-Coquard I, Mirza MR, Pignata S, Walther A, Romero I and du Bois A: Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. Cancer Treat Rev. 90:1021072020. View Article : Google Scholar : PubMed/NCBI
6	Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
7	Deb B, Uddin A and Chakraborty S: miRNAs and ovarian cancer: An overview. J Cell Physiol. 233:3846–3854. 2018. View Article : Google Scholar : PubMed/NCBI
8	Mihanfar A, Fattahi A and Nejabati HR: MicroRNA-mediated drug resistance in ovarian cancer. J Cell Physiol. 234:3180–3191. 2019. View Article : Google Scholar : PubMed/NCBI
9	Dinh P, Harnett P, Piccart-Gebhart MJ and Awada A: New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol. 67:103–112. 2008. View Article : Google Scholar : PubMed/NCBI
10	Smolle E, Taucher V, Pichler M, Petru E, Lax S and Haybaeck J: Targeting signaling pathways in epithelial ovarian cancer. Int J Mol Sci. 14:9536–9555. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xu L, Wu H, Jiang C, Wang H, Gao B, Yan S, Qi Y and Zhou S: Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells. Discov Med. 22:297–309. 2016.PubMed/NCBI
12	Camblin AJ, Tan G, Curley MD, Yannatos I, Iadevaia S, Rimkunas V, Mino-Kenudson M, Bloom T, Schoeberl B, Drummond DC, et al: Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 9:168322019. View Article : Google Scholar : PubMed/NCBI
13	Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, et al: Hematogenous metastasis of ovarian cancer: Rethinking mode of spread. Cancer Cell. 26:77–91. 2014. View Article : Google Scholar : PubMed/NCBI
14	Li LW, Xiao HQ, Ma R, Yang M, Li W and Lou G: miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3. Int J Mol Med. 41:1529–1535. 2018.PubMed/NCBI
15	Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH and Barrett E: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer. 15:785–792. 2005. View Article : Google Scholar : PubMed/NCBI
16	Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H and Godwin AK: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A gynecologic oncology group study. Clin Cancer Res. 11:5539–5548. 2005. View Article : Google Scholar : PubMed/NCBI
17	Liao BC, Lin CC and Yang JC: Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 27:94–101. 2015. View Article : Google Scholar : PubMed/NCBI
18	Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, et al: Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 7:42042017. View Article : Google Scholar : PubMed/NCBI
19	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wu J, Zhang L, Li H, Wu S and Liu Z: Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression. Biochem Biophys Res Commun. 518:698–705. 2019. View Article : Google Scholar : PubMed/NCBI
21	Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, et al: Chronic IL-1beta-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Sci Rep. 10:3772020. View Article : Google Scholar : PubMed/NCBI
22	Miao Y, Liu G and Liu L: Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma. Cancer Cell Int. 21:22021. View Article : Google Scholar : PubMed/NCBI
23	Zhao L, Fan T, Shi Z, Ding C, Zhang C, Yuan Z, Sun Q, Tan C, Chu B and Jiang Y: Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR^T790M mutant cell lines. Eur J Med Chem. 213:1131732021. View Article : Google Scholar : PubMed/NCBI
24	Hyokai S, Tanaka H, Aihara N and Kamiie J: Expression of P-glycoprotein and breast cancer resistance protein in three cases of canine lymphoma showing drug resistance. J Vet Med Sci. Jan 29–2021.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
25	Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ and Langdon SP: Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer. 106:1779–1789. 2012. View Article : Google Scholar : PubMed/NCBI
26	Toolabi M, Moghimi S, Bakhshaiesh TO, Salarinejad S, Aghcheli A, Hasanvand Z, Nazeri E, Khalaj A, Esmaeili R and Foroumadi A: 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies. Eur J Med Chem. 185:1117862020. View Article : Google Scholar : PubMed/NCBI
27	Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH, Hao ZJ, Tian B, He HW and Guo XL: Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother. 120:1094782019. View Article : Google Scholar : PubMed/NCBI
28	Hao Sun and Wu YL: Dacomitinib in non-small-cell lung cancer: A comprehensive review for clinical application. Future Oncol. 15:2769–2777. 2019. View Article : Google Scholar : PubMed/NCBI
29	Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, et al: Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 11:58242020. View Article : Google Scholar : PubMed/NCBI
30	Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, et al: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: Study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 21:3912020. View Article : Google Scholar : PubMed/NCBI
31	Huang X and Tang J: Human la protein: An RNA-binding protein involved in ovarian cancer development and multidrug resistance. Onco Targets Ther. 13:10721–10727. 2020. View Article : Google Scholar : PubMed/NCBI
32	Passaro A, Mok T, Peters S, Popat S, Ahn MJ and de Marinis F: Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol. S1556-0864:31102–31103. 2020.(Epub ahead of print).
33	Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 67:11924–11932. 2007. View Article : Google Scholar : PubMed/NCBI
34	Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, et al: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 7:1880–1889. 2008. View Article : Google Scholar : PubMed/NCBI
35	Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi H, Masuda J, Ozawa H and Ogiwara Y: Targeting oncoimmune drivers of cancer metastasis. Cancers (Basel). 13:5542021. View Article : Google Scholar : PubMed/NCBI
36	Klymenko Y, Kim O and Stack MS: Complex determinants of epithelial: Mesenchymal phenotypic plasticity in ovarian cancer. Cancers (Basel). 9:1042017. View Article : Google Scholar : PubMed/NCBI
37	Ahmed AR and Muhammad EM: E-cadherin and CD10 expression in atypical hyperplastic and malignant endometrial lesions. J Egypt Natl Canc Inst. 26:211–217. 2014. View Article : Google Scholar : PubMed/NCBI
38	Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
39	Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 81:116–124. 1989. View Article : Google Scholar : PubMed/NCBI
40	Muthiah D, Henshaw GK, DeBono AJ, Capuano B, Scammells PJ and Callaghan R: Overcoming P-glycoprotein-mediated drug resistance with noscapine derivatives. Drug Metab Dispos. 47:164–172. 2019. View Article : Google Scholar : PubMed/NCBI
41	Chen Q, Liu X, Luo Z, Wang S, Lin J, Xie Z, Li M, Li C, Cao H, Huang Q, et al: Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression. J Cell Physiol. 234:6611–6623. 2019. View Article : Google Scholar : PubMed/NCBI
42	Xu L, Cai J, Yang Q, Ding H, Wu L, Li T and Wang Z: Prognostic significance of several biomarkers in epithelial ovarian cancer: A meta-analysis of published studies. J Cancer Res Clin Oncol. 139:1257–1277. 2013. View Article : Google Scholar : PubMed/NCBI
43	Poursheikhani A, Yousefi H, Tavakoli-Bazzaz J and Seyed HG: EGFR blockade reverses cisplatin resistance in human epithelial ovarian cancer cells. Iran Biomed J. 24:370–378. 2020.PubMed/NCBI
44	Perrotta C, Cervia D, Di Renzo I, Moscheni C, Bassi MT, Campana L, Martelli C, Catalani E, Giovarelli M, Zecchini S, et al: Nitric oxide generated by tumor-associated macrophages is responsible for cancer resistance to cisplatin and correlated with syntaxin 4 and acid sphingomyelinase inhibition. Front Immunol. 9:11862018. View Article : Google Scholar : PubMed/NCBI
45	Xu H, Zhang Z, Li P, Lu X, Chen B and Lan T: Expression of PKG2 in ovarian cancer and its effect on epidermal growth factor receptor. J BUON. 25:729–735. 2020.PubMed/NCBI
46	Pang J, Jiang P, Wang Y, Jiang L, Qian H, Tao Y, Shi R, Gao J, Chen Y and Wu Y: Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma. J Ovarian Res. 11:222018. View Article : Google Scholar : PubMed/NCBI